Thalidomide in multiple myeloma

P. Richardson; T. Hideshima; K. Anderson

doi:10.1016/S0753-3322(02)00168-3

Thalidomide in multiple myeloma

P. Richardson, T. Hideshima, K. Anderson

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Thalidomide - removed from widespread clinical use by 1962 because of severe teratogenicity - has anti-angiogenic and immunomodulatory effects, including the inhibition of TNF alpha. It has returned to practice as an effective oral agent in the management of various disease states including erythema nodosum leprosum, for which it was FDA-approved in 1998, and more recently certain malignancies, including multiple myeloma. Whilst the mechanism of action of thalidomide remains incompletely understood, considerable insight has been generated by extensive preclinical studies in multiple myeloma. Moreover, clinical trials both as a single agent and in combination have confirmed benefit in relapsed and refractory disease. Thalidomide's role in treating newly diagnosed patients is currently under study and it is now established as an important therapeutic option in the treatment of multiple myeloma.

Original language	English (US)
Pages (from-to)	115-128
Number of pages	14
Journal	Biomedicine and Pharmacotherapy
Volume	56
Issue number	3
DOIs	https://doi.org/10.1016/S0753-3322(02)00168-3
State	Published - 2002
Externally published	Yes

Keywords

Anti-angiogenesis
Immunomodulation
Myeloma
Thalidomide

ASJC Scopus subject areas

Pharmacology

Access to Document

10.1016/S0753-3322(02)00168-3

Cite this

@article{cac44f16eb90428f89d53adc829b0bbd,

title = "Thalidomide in multiple myeloma",

abstract = "Thalidomide - removed from widespread clinical use by 1962 because of severe teratogenicity - has anti-angiogenic and immunomodulatory effects, including the inhibition of TNF alpha. It has returned to practice as an effective oral agent in the management of various disease states including erythema nodosum leprosum, for which it was FDA-approved in 1998, and more recently certain malignancies, including multiple myeloma. Whilst the mechanism of action of thalidomide remains incompletely understood, considerable insight has been generated by extensive preclinical studies in multiple myeloma. Moreover, clinical trials both as a single agent and in combination have confirmed benefit in relapsed and refractory disease. Thalidomide's role in treating newly diagnosed patients is currently under study and it is now established as an important therapeutic option in the treatment of multiple myeloma.",

keywords = "Anti-angiogenesis, Immunomodulation, Myeloma, Thalidomide",

author = "P. Richardson and T. Hideshima and K. Anderson",

year = "2002",

doi = "10.1016/S0753-3322(02)00168-3",

language = "English (US)",

volume = "56",

pages = "115--128",

journal = "Biomedicine and Pharmacotherapy",

issn = "0753-3322",

publisher = "Elsevier Masson",

number = "3",

}

TY - JOUR

T1 - Thalidomide in multiple myeloma

AU - Richardson, P.

AU - Hideshima, T.

AU - Anderson, K.

PY - 2002

Y1 - 2002

N2 - Thalidomide - removed from widespread clinical use by 1962 because of severe teratogenicity - has anti-angiogenic and immunomodulatory effects, including the inhibition of TNF alpha. It has returned to practice as an effective oral agent in the management of various disease states including erythema nodosum leprosum, for which it was FDA-approved in 1998, and more recently certain malignancies, including multiple myeloma. Whilst the mechanism of action of thalidomide remains incompletely understood, considerable insight has been generated by extensive preclinical studies in multiple myeloma. Moreover, clinical trials both as a single agent and in combination have confirmed benefit in relapsed and refractory disease. Thalidomide's role in treating newly diagnosed patients is currently under study and it is now established as an important therapeutic option in the treatment of multiple myeloma.

AB - Thalidomide - removed from widespread clinical use by 1962 because of severe teratogenicity - has anti-angiogenic and immunomodulatory effects, including the inhibition of TNF alpha. It has returned to practice as an effective oral agent in the management of various disease states including erythema nodosum leprosum, for which it was FDA-approved in 1998, and more recently certain malignancies, including multiple myeloma. Whilst the mechanism of action of thalidomide remains incompletely understood, considerable insight has been generated by extensive preclinical studies in multiple myeloma. Moreover, clinical trials both as a single agent and in combination have confirmed benefit in relapsed and refractory disease. Thalidomide's role in treating newly diagnosed patients is currently under study and it is now established as an important therapeutic option in the treatment of multiple myeloma.

KW - Anti-angiogenesis

KW - Immunomodulation

KW - Myeloma

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=0036227466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036227466&partnerID=8YFLogxK

U2 - 10.1016/S0753-3322(02)00168-3

DO - 10.1016/S0753-3322(02)00168-3

M3 - Article

C2 - 12046682

AN - SCOPUS:0036227466

SN - 0753-3322

VL - 56

SP - 115

EP - 128

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

IS - 3

ER -

Thalidomide in multiple myeloma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this